Correction to: Radiopharmaceutical tracers for cardiac imaging

Osamu Manabe, MD, PhD,[a] Tatsuya Kikuchi, PhD,[b] Arthur J. H. A. Scholte, MD, PhD,[c] Mohammed El Mahdiui, MD,[c] Ryuichi Nishii, MD, PhD,[d] Ming-Rong Zhang, PhD,[b] Eriko Suzuki, LT,[a] and Keiichiro Yoshinaga, MD, PhD, FACC, FASNC[d]

[a] Department of Nuclear Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan
[b] Department of Radiopharmaceutical Development, National Institutes for Quantum and Radiological Science and Technology, National Institute of Radiological Sciences, Chiba, Japan
[c] Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands
[d] Diagnostic and Therapeutic Nuclear Medicine, National Institutes for Quantum and Radiological Science and Technology, National Institute of Radiological Sciences, Chiba, Japan

doi:10.1007/s12350-018-1184-0

CORRECTION TO: J NUCL CARDIOL
HTTPS://DOI.ORG/10.1007/S12350-017-1131-5

Regrettably the original version of the above article contained errors in the three chemical structures presented in the 'Atherosclerosis imaging' section of Table 5, namely: ^{99m}Tc annexin V, ^{68}Ga DOTATATE, and ^{64}Cu DOTATATE; the chemical structures have been corrected in Table 5 presented here. In addition, the radiopharmaceutical for isotope ^{67}Ga has been corrected to ^{67}Ga citrate, and many of the radiopharmaceuticals presented at the end of the table have been corrected.

The original article can be found online at https://doi.org/10.1007/s12350-017-1131-5.

Reprint requests: Keiichiro Yoshinaga, MD, PhD, FACC, FASNC, Diagnostic and Therapeutic Nuclear Medicine, National Institutes for Quantum and Radiological Science and Technology, National Institute of Radiological Sciences, 4-9-1 Anagawa, Inage-Ku, Chiba 263-8555, Japan; *yoshinaga.keiichiro@qst.go.jp*

J Nucl Cardiol 2018;25:1237–41.
1071-3581/$34.00

Table 5. Inflammation and atherosclerosis imaging

Isotope	Radiopharmaceutical	Chemical structure	Type of tracer	Study population
General inflammation				
^{18}F	^{18}F-FDG		Organic compound	Carotid and coronary plaque imaging Cardiac sarcoidosis Device infection
^{67}Ga	^{67}Ga citrate	$^{67}Ga^{3+}$	Metal cation	Inflammatory heart disease Cardiac sarcoidosis
Infection				
^{111}In	^{111}In WBC	-	Radiolabeled cell	Infectious disease
Atherosclerosis imaging				
^{99m}Tc	^{99m}Tc annexin 5		Radiometal-tagged Annexin V	Apoptosis imaging

Table 5 continued

Isotope	Radiopharmaceutical	Chemical structure	Type of tracer	Study population
^{68}Ga	^{68}Ga DOTATATE		Radiometal-tagged octreotide analog	Symptomatic carotid atherosclerosis Unstable angina
^{64}Cu	^{64}Cu DOTATATE		Radiometal-tagged octreotide analog	Symptomatic carotid atherosclerosis

Table 5 continued

Isotope	Radiopharmaceutical	Chemical structure	Type of tracer	Study population
Translocator protein				
^{11}C	^{11}C-PK11195		Organic compound	Symptomatic carotid atherosclerosis
^{18}F	^{18}F-FEDAC		Organic compound	
^{18}F	^{18}F-NaF	$^{18}F^-$	Inorganic anion	Aortic stenosis Coronary artery disease Carotid artery plaque

Table 5. continued

Radiopharmaceutical	Characteristics	Approval year		
		FDA	Europe	Japan
General inflammation				
^{18}F-FDG	Accumulating macrophage Strong signal Limitation: non-specific myocardial accumulation	-	1994*	2012 (cardiac sarcoidosis)
^{67}Ga citrate	No physiological uptake Limitation: suboptimal image quality	1976	1972*	1982
Infection				
^{111}In WBC	Accumulates in WBC Limitation: suboptimal image quality	1985	1980**	1992
Atherosclerosis imaging				
^{99m}Tc annexin 5	Lesion specific Limitation: weak signal intensity	-	-	-
^{68}Ga DOTATATE	Accumulates activated macrophages No physiological myocardial uptake Generator produced	2016	-	-
^{64}Cu DOTATATE	Good image quality	-	-	-
Translocator protein				
^{11}C-PK11195	Accumulates in activated mononuclear phagocyte	-	-	-
^{18}F-FEDAC	Accumulates in activated mononuclear phagocyte High affinity and better image quality	-	-	-
^{18}F-NaF	Accumulates in calcification lesion	2012	-	-

^{68}Ga DOTATATE Gallium-68-labeled [1,4,7,10-tetraazacyclododecane-*N*,*N*′,*N*″,*N*‴-tetraacetic acid]-d-Phe^{1}, Tyr^{3}-octreotate, *^{18}F-FDG* ^{18}F-fluorodeoxyglucose, *^{18}F-FEDAC* *N*-benzyl-*N*-methyl-2-[7,8-dihydro-7-(2-[^{18}F]fluoroethyl)-8-oxo-2-phenyl-9*H*-purin-9-yl]acetamide, *WBC* white blood cell
*EURD List Juli 2017: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2012/10/WC500133159.xls
**EURD list 2012: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2012/04/WC500124999.xls